Drug Trial Radar · NCT07710885
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
784
Planned (sponsor's estimate)
Start
Jun 24, 2026
Primary completion
Apr 30, 2030
Study completion Dec 31, 2031
Sponsor
- Lead sponsor
- Taiho Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Taiho Oncology, Inc.
- First posted
- Jul 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare overall survival (OS) of patients in Futibatinib and Zimberelimab in Combination with Gemcitabine plus Cisplatin versus Durvalumab or Pembrolizumab in Combination with Gemcitabine plus Cisplatin for patients with first-line advanced biliary tract cancer
Conditions
- Biliary Tract Cancer
Interventions
FutibatinibDrug
Futibatinib 20 mg will be administered orally once daily.
ZimberelimabDrug
Zimberelimab 360 mg will be administered on Day 1 of each 3-week cycle (Q3W) by intravenous infusion.
DurvalumabDrug
Durvalumab 1500 mg will be administered on Day 1 of Q3W by intravenous infusion.
PembrolizumabDrug
Pembrolizumab 200 mg will be administered on Day 1 of Q3W by intravenous infusion.
GemcitabineDrug
Gemcitabine 1000 mg/m2 will be administered Days 1 and 8 of Q3W by intravenous infusion.
CisplatinDrug
Cisplatin 25 mg/m2 will be administered Days 1 and 8 of Q3W by intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to approximately 45 months
Locations
21 sites in 4 countries. Site status is shown where the registry gives one.
Research Site
Brisbane, Australia · Not yet recruiting
Research Site
Melbourne, Australia · Not yet recruiting
Research Site
Perth, Australia · Not yet recruiting
Research Site
Sydney, Australia · Not yet recruiting
Research Site
Aichi, Japan · Not yet recruiting
National Hospital Organization Kyushu Cancer Center
Fukuoka, Japan · Recruiting
Research Site
Fukuoka, Japan · Not yet recruiting
Research Site
Hokkaido, Japan · Not yet recruiting
Kanagawa Cancer Center
Kanagawa, Japan · Not yet recruiting
Research Site
Miyagi, Japan · Not yet recruiting
Research Site
Osaka, Japan · Not yet recruiting
Research Site
Tokyo, Japan · Not yet recruiting
The Cancer Institute Hospital
Tokyo, Japan · Recruiting
Toyama University Hopspital
Toyama, Japan · Recruiting
Wakayama Medical University Hospital
Wakayama, Japan · Recruiting
Research Site
Busan, South Korea · Not yet recruiting
Research Site
Hwasun, South Korea · Not yet recruiting
Research Site
Seongnam, South Korea · Not yet recruiting
Research Site
Seoul, South Korea · Not yet recruiting
Research Site
Bangkok, Thailand · Not yet recruiting
Research Site
Chiang Mai, Thailand · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.